

1127  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KOPCHICK, et al.

Serial No.: 08/488,164

Filed: June 7, 1995

For: DNA ENCODING GROWTH  
HORMONE ANTAGONISTS

Art Unit: 1647

Examiner: SAOUD, C.

Washington, D.C.


November 29, 2000

Docket No.: KOPCHICK=1E

RECEIVED

DEC 04 2000

TECH CENTER 1600/2900



RESPONSE TO SUPPLEMENTAL ACTION

Honorable Commissioner of Patents  
Washington, D.C. 20231

S i r :

The supplemental action mailed October 24 was not made final, so we assume that finality has been withdrawn. This is consistent with the paragraph bridging pp. 2-3 of the Action, and the last para. on page 4.

Applicants assume that the Amendment filed July 28 has been entered. However, if it has not been entered, we request that it be entered, and incorporate it by reference into this response.

The previously examined claims were 10-44, 62, 63, and 65-74. The July 28 amendment amended claims 10, 19-24, 26, 29-35, 38, 39, 46, 63 and 64, and added claims 75-106. As a result, claims 10-44, 62, 63 and 65-106 are pending (45 is withdrawn from consideration).

To facilitate examination, applicants have prepared a "pending claims set". The Examiner is requested to bring any errors in this set to Applicants' attention. Naturally, if there is a discrepancy between this "pending claims set" and the official record, the latter controls.

1. The main purpose of the supplemental action was to clarify the treatment of claim 63. In the January 31, 2000